

**19-NOV-2017 6:11
OPEN STUDIES IRB REPORT**

06:10 Sunday, November 19, 2017 1

Disease Site	Study	Study Name	Open Date	Number of Active Institutions	Number of Current IRBs
BREAST	S1207	Brst,Adj,Endocrine+/-Everolimus	03-SEP-13	452	235
	S1416	Brst, TNBC/BRCA, Cis+/- ABT-888	07-JUL-16	264	126
	S1418	Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	15-NOV-16	389	175
	A011106	Breast, Neoadj, ALTERNATE study	15-FEB-14	247	116
	A011401	Breast, adj, Stage II/III HER2-, weight loss	29-AUG-16	425	229
	A011502	Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	08-DEC-16	0	197
	A221405	Breast, ET interruption, Pregnancy Outcomes	15-OCT-15	0	58
	B55	Brst, Adj Olaparib for BRCA,TNBC	03-JUL-14	408	180
	E1Z11	Brst,Genetic Predictors of AIMSS	10-MAY-13	227	81
	E2112	Brst,Adv,Exemestane+/-Entinostat	02-JAN-14	285	167
	NRGBR002	Brst, OMBC, II-III, SoC +/- SBRT and/or SA	24-DEC-14	0	4
	NRGBR003	Brst,Adj,TNBC,AC -> WP +/- Carbo	22-JAN-15	447	229
	CCD	S1415CD	TrACER CSF Standing Order Intervention for FN	01-SEP-16	20
S1417CD		Colorectal, Cost Cohort Study	13-MAY-16	199	60
A011104		Preoperative Breast MRI	21-FEB-14	168	60
ERLYTX	S1609	Rare Tumor, Comb Nivo/Ipi	13-JAN-17	345	147
	A071102	GBM, adj TMZ +/- Veliparib	19-SEP-14	373	162
	A071401	Prog Meningiomas,SMO/AKT/NF2 Inhib	06-AUG-15	245	104
	ARST1321	NonRhabdo STS,Pazopanib (PAZNTIS)	16-MAY-14	241	117
	EAY131	MATCH	12-AUG-15	466	244
GI	S1505	Panc,Resect, Perioperative Chemo	12-OCT-15	310	124
	S1513	Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888	01-SEP-16	319	149
	S1613	mCRC, Adv/Met, TP vs CETIRI	09-OCT-17	0	28
	A021501	Adeno Panc,Borderline Resect,Chemo vs ChemoRT	01-DEC-16	0	50
	EA2133	Anal, local recur/met, Cis+5FU vs Taxol/Carbo	29-JAN-16	0	40
	EA2142	GI NEC, Adv G3, EP vs TMZ + CAP	06-NOV-15	185	71
	N1048	Rectal,LocalAdv,ChemoRT+/-FOLFOX	13-JAN-12	0	161
	NRGGI002	Rectal, Ph II, Sensitization using TNT	12-OCT-16	320	132
	R0848	Panc, Adj, Erlotinib v ChemoRT	01-MAR-14	0	148
GU	S1314	Blad, COXEN Neoadj. Chemo + Cyst	11-JUL-14	212	108
	S1500	pRCC,Adv, Sunitinib vs MET inhib	05-APR-16	207	92
	S1602	Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	07-FEB-17	143	64
	S1605	Blad, BCG-Unresponsive NMIBC, Atezolizumab	07-FEB-17	140	63

19-NOV-2017 6:11
OPEN STUDIES IRB REPORT

06:10 Sunday, November 19, 2017 2

Disease Site	Study	Study Name	Open Date	Number of Active Institutions	Number of Current IRBs
	A031102	GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	01-JUL-15	59	35
	EA8141	UTUC, HG, Chemo then Surg	27-JAN-15	154	75
	EA8143	RCC, HR, Surg +/- Nivolumab (PROSPER)	02-FEB-17	0	4
	NRGGU002	Pros, RT + ADT After RP +/- Adj Docetaxel	30-DEC-16	0	103
	R0924	Pros, NADT+WPRT vs. NADT+P&SV RT	07-JUL-11	0	162
LEUK	S1312	ALL, CD22+, REL/REF, Inotuzumab+CVP	01-APR-14	1	2
	E1910	BCR-ABL-neg, B ALL, Blinatumomab	23-DEC-13	157	86
	E2906	AML, Age 60+, Clo vs Dauno+Cy	24-FEB-11	150	80
	NHLBIMDS	LEUK, National MDS Study	05-APR-16	254	104
LUNG	S1400	SCCA,Adv, Biomarker Master	15-JUN-14	437	218
	S1400F	Non-Match: MEDI4736 + Tremelimumab	02-OCT-17	0	201
	S1400G	HRRD: Talazoparib (BMN 673)	07-FEB-17	439	219
	S1400I	Non-Match: Nivo + Ipi vs Nivo	18-DEC-15	434	217
	S1403	Adv,EGFR-mt,Afatinib+/-Cetuximab	25-MAR-15	225	95
	S1507	NSCLC, Adv, Kras Mut, Trametinib + Docetaxel	18-JUL-16	208	92
	A081105	ALCHEMIST1, EGFR mut, Erlotinib	02-JAN-14	0	248
	A151216	ALCHEMIST0 - screening	06-FEB-14	452	251
	C30610	SCLC, Thoracic RT	21-MAR-08	239	118
	E4512	ALCHEMIST2, ALK mut, Crizotinib	18-AUG-14	456	257
	EA5142	ALCHEMIST3, Non-match, Nivolumab	16-MAY-16	406	230
	NRGCC003	SCLC, PCI or HA-PCI	07-DEC-15	320	143
	R1306	NSCLC,Adv,ALK/EGFR,TargetAgents	04-NOV-13	189	79
LYMPH	S1608	Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob	10-AUG-17	0	58
	A051301	ABC DLBCL, Auto HCT and Ibrutinib/Placebo	15-JUL-16	133	61
MELAN	S1320	Adv, BRAF mut, Inter v Contin	22-JUL-14	229	102
	S1404	Melan, Adv, HD-IFN/Ipilimumab vs MK-3475	15-OCT-15	390	170
	S1512	Melan, Adv, Desmoplastic, MK-3475 (pembro)	20-OCT-16	73	31
	S1607	MELAN, Adv, T-VEC, MK-3475	02-OCT-17	0	6
	S1616	MELAN, Adv, Ipilimumab ± Nivolumab	17-JUL-17	0	54
	EA6134	Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	15-DEC-15	350	144
	EA6141	Melan, Adv, Nivolumab+Ipi ± Sargmostim	01-MAR-16	312	126
MMYEL	E1A11	MM, frontline, BLD vs CLD	22-NOV-13	314	137

**19-NOV-2017 6:11
OPEN STUDIES IRB REPORT**

<u>Disease Site</u>	<u>Study</u>	<u>Study Name</u>	<u>Open Date</u>	<u>Number of Active Institutions</u>	<u>Number of Current IRBs</u>	
OTHER	A091202	Sarc, Efatutazone vs Placebo, Unresect ,Lipo	02-SEP-14	51	29	
	A091304	Adv Sarc, MLN0128 v Pazopanib, Phi/II	26-JAN-15	185	65	
	A091305	HN, Adv, Thyroid PPAR agonist + Chemo	01-SEP-14	120	38	
	A091401	Sarc,	18-JUN-15	233	91	
	A091404	HN, AR+, Enzalutamide	25-SEP-15	93	39	
	EA3132	HN SCC, Stg III-IV , Adj RT +/- Cisp	29-MAR-16	0	64	
	EAQ152	Communication & education in tumor profiling	26-SEP-16	241	104	
	G0263	Cerv, Stg I/IIA, adjv RT vs chemoRT	12-APR-10	0	6	
	G0281	Ovar, Recur/prog LG, IC chemo vs trametinib	27-FEB-14	0	82	
	NRGBN001	HN, novel vs. std chemoradiation + chemo	28-AUG-15	0	109	
	NRGGY004	Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo	04-FEB-16	344	163	
	NRGGY005	OVAR, Cedir vs Olaparib vs C+O vs Std of Care	06-FEB-16	317	141	
	NRGHN001	Nasopharyngeal , Individual Tx EBV	21-APR-14	191	69	
	R0724	Cervical, Chem+RT +/- Adj. Chemo	15-JAN-14	247	98	
	R0920	HN, Adv, Postop IMRT ± Cetuximab	24-DEC-13	327	151	
	R1216	HN, Adv,Cis vs Dtx vs Dtx+Cetux	18-MAR-13	274	121	
	PREV	S0820	PACES: ColrecStg0-3 Blind DFMO/Sulindac	01-MAR-13	329	114
		A211102	Breast, Atypia via RPFNA, Metformin v Placebo	01-FEB-15	25	10
		A211201	Breast Density, MA.32 companion	22-AUG-12	18	12
		EA1141	Breast, Abbrev. MRI vs Digital Tomosynthesis	02-SEP-16	0	10
SURV	S1316	Compar. Effectiv. Trial for MBO	09-MAR-15	14	19	
	S1501	Surv, Breast Stg IV, Card Tox w/ Carvedilol	15-SEP-17	0	25	
	E1Q11	EROS: Reproductive Health in Cancer Survivors	30-SEP-15	0	36	
	EA9131	Leuk, Strategy to decrease early APL deaths	16-AUG-17	0	15	
SXQOL	A221101	Glioma, Nuvigil/Placebo Fatigue	03-JUN-13	207	91	
	A221102	Brst,Al Arthralgia,Testosterone	07-SEP-12	0	56	